Editas Medicine, Inc. (NASDAQ:EDIT) Jumps in Trading Today – Up by 4.09% – Modern Readers
|
Editas Medicine, Inc. (NASDAQ:EDIT) Jumps in Trading Today – Up by 4.09%
Modern Readers CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either Cas9 (CRISPR associated protein 9) or Cpf1 (CRISPR from Prevotella and Francisella 1), bound to a guide RNA molecule designed to recognize a particular … |
BioEdge |
Spanish researcher snagged in stem cell research fraud
BioEdge The biggest-ever fraud in Spanish science is coming to light – and like other recent frauds, it centres on stem cell research. Earlier this week the journal Molecular and Cellular Biology retracted a 2003 paper by Susana Gonzalez, an experienced … |
Cancer Research UK (blog) |
News digest – lung cancer drug, vaping, HPV, and… CRISPR genome editing?
Cancer Research UK (blog) We reported on a promising immunotherapy drug, nivolumab (Opdivo), being made available to certain lung cancer patients in England. NICE, who decides on availability of NHS treatments, said it could be given to patients with advanced non-small cell … |